Suchergebnisse - "d'Ettorre, Gabriella"

PubPharm (11)

1

Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients : Data from real-life ODOACRE cohort

enthalten in: HIV medicine | 2021

von Fabbiani, M. | Rossetti, B. | Ciccullo, A. | +31

2

Overall Tolerability of Integrase Inhibitors in Clinical Practice : Results from a Multicenter Italian Cohort

enthalten in: AIDS research and human retroviruses | 2021

von Ciccullo, A. | Baldin, G. | Borghi, V. | +12

3

Real word outcomes associated with use of raltegravir in older people living with HIV : results from the 60 months follow-up of the RAL-age cohort

enthalten in: Expert review of anti-infective therapy | 2020

von Santinelli, L. | Ceccarelli, G. | Borrazzo, C. | +10

4

A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study)

enthalten in: PloS one | 2019

von Mussini, C. | Roncaglia, E. | Borghi, V. | +15

5

Long-Term Treatment With Raltegravir is Associated with Lower Triglycerides and Platelets Count in the Older HIV+ Population : Results from the Ral-Age Study

enthalten in: Current HIV research | 2017

von Pavone, P. | Giustini, N. | Fimiani, C. | +8

6

Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification : a multicenter observational study

enthalten in: BMC infectious diseases | 2016

von Latini, A. | Fabbiani, M. | Borghi, V. | +11

7

Dynamics of HIV DNA and residual viremia in patients treated with a raltegravir-containing regimen

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2015

von Falasca, F. | Mazzuti, L. | DʼEttorre, G. | +5

8

Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens

enthalten in: AIDS research and human retroviruses | 2015

von Baroncelli, S. | Pirillo, M. | Galluzzo, C. | +12

9

Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control : 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study)

enthalten in: Scandinavian journal of infectious diseases | 2014

von Fabbiani, M. | Mondi, A. | Colafigli, M. | +11

10

Effects of raltegravir on 2-long terminal repeat circle junctions in HIV type 1 viremic and aviremic patients

enthalten in: AIDS research and human retroviruses | 2013

von Bona, R. | Baroncelli, S. | D'Ettorre, G. | +10